Male Hypogonadism
18
1
2
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
39%
7 trials in Phase 3/4
67%
8 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (18)
Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism
PREDICTORS OF TESTOSTERONE DECLINE IN MIDDLE-AGED MEN
Testosterone in Bariatric Patients
Testosterone Undecanoate Replacement Therapy in Boys With Pubertal Delay or Confirmed Hypogonadism
Relationship of the Microenvironment and Male Fertility
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
D-chiroinositol Administration in Hypogonadal Males
Pharmacokinetic Study to Determine Time to Steady-state
Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism
5-Alpha Reductase and Anabolic Effects of Testosterone
Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
Safety and Efficacy Trial of Testosterone Undecanoate
Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
Time to Eugonadal Range, Time to Steady State and Drying Time
Autonomic Manifestations of Testosterone Deficiency in Men
Registry of Hypogonadism in Men